Showing results (261-270 of 301) with videos related to
Sort By:
Pageof 31
Cancers|April 23, 2020
Ex Vivo Assessment of Tumor-Targeting Fluorescent Tracers for Image-Guided SurgeryFortuné M K Elekonawo, Jan Marie de Gooyer, Desirée L Bos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignanciesYicheng Mao, Georgia Triantafillou, Erin Hertlein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2012
Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancerRafke Schoffelen, Winette T A van der Graaf, Robert M Sharkey, et al.Clinical Lymphoma|July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai, Ivan Maillard, Stephen J Schuster, et al.Rheumatology (Oxford, England)|April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-upDaniel J Wallace, Caroline Gordon, Vibeke Strand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.The Journal of Clinical Endocrinology and Metabolism|September 20, 2007
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapyAurore Oudoux, Pierre-Yves Salaun, Claire Bournaud, et al.Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Pageof 31